# US 2012/0252843 A1 · Isoindoline compounds and methods of their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252843 A1
- Document ID: US20120252843A1
- Status: Published application
- Kind: A1
- Application number: 13/493,808
- Filed: 2012-06-11
- Published: 2012-10-04
- Earliest claimed: 2008-10-29
- Assignees: Celgene Corporation
- Inventors: George W. Muller; Alexander L. Ruchelman
- Web page: https://patentgrep.com/patent/US20120252843A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/20: Hypnotics; Sedatives
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 29/02: without antiinflammatory effect
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein are isoindoline compounds, pharmaceutical compositions comprising one or more of such compounds, and methods of their use for treating, preventing, or managing various diseases.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A compound of Formula V:
or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof, wherein:
X is C(═O) or CH2;
m is an integer of 0, 1, 2, or 3;
R10 and R11 are each independently hydrogen, halo, C1-6 alkyl, or C6-10 aryloxy,
wherein the alkyl and aryl are each optionally substituted with one or more halo.

### Claim 17 (depends on 16)

The compound of claim 16, which is:
or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof.

### Claim at position 4

18-20. (canceled)

### Claim 21 (depends on 16)

A pharmaceutical composition comprising the compound of claim 16, and one or more pharmaceutically acceptable excipients or carriers.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, further comprising a second therapeutic agent.

### Claim 23 (depends on 21)

The pharmaceutical composition of claim 21, wherein the composition is formulated for single dose administration.

### Claim 24 (depends on 21)

The pharmaceutical composition of claim 21, wherein the composition is formulated as oral, parenteral, or intravenous dosage form.

### Claim 25 (depends on 24)

The pharmaceutical composition of claim 24, wherein the oral dosage form is a tablet or capsule.

### Claim at position 10

26-30. (canceled)

### Claim 31 (depends on 16)

A method of treating or managing cancer comprising administering to a subject a therapeutically effective amount of a compound of claim 16, wherein the cancer is Non-Hodgkin's lymphoma, Hodgkin's lymphoma, diffuse large B-cell lymphoma, Burkitt's lymphoma, or cutaneous T-cell lymphoma.

### Claim 32 (depends on 31)

The method of claim 31, which further comprises administration of one or more additional agents.

### Claim 33 (depends on 31)

The method of claim 31, wherein the compound is administered orally or parenterally.

### Claim 34 (depends on 16)

A method of treating or managing cancer comprising administering to a subject a therapeutically effective amount of a compound of claim 16, wherein the cancer is prostate cancer, pancreatic cancer, breast cancer or colorectal cancer.

### Claim 35 (depends on 34)

The method of claim 34, which further comprises administration of one or more additional agents.

### Claim 36 (depends on 34)

The method of claim 34, wherein the compound is administered orally or parenterally.

### Claim 37 (depends on 16)

The compound of claim 16, wherein X is CH2.

### Claim 38 (depends on 16)

The compound of claim 16, wherein m is 1.
